Exciting Times for Cytomegalovirus (CMV) Vaccine Development: Navigating the Pathways Toward the Goal of Protecting Infants Against Congenital CMV Infection

Overview

Journal Vaccines (Basel)

Date 2020 Sep 17

PMID 32937764

Citations 8

Authors

Mark R Schleiss

Don J Diamond

Affiliations

Soon will be listed here.

Abstract

The congenital transmission of cytomegalovirus (cCMV) is the most common infectious cause of disability in children in the developed world, and probably globally [...].

Citing Articles

Primary, Secondary, and Tertiary Prevention of Congenital Cytomegalovirus Infection.

Sartori P, Egloff C, Hcini N, Vauloup Fellous C, Perillaud-Dubois C, Picone O Viruses. 2023; 15(4).

PMID: 37112800 PMC: 10146889. DOI: 10.3390/v15040819.

Diversity of the cochlear and vestibular pathologies in human temporal bones of newborns infected with cytomegalovirus.

Tsuprun V, Schleiss M, Cureoglu S Ann Clin Pathol. 2023; 9(1).

PMID: 37008271 PMC: 10062439.

Lessons from Acquired Natural Immunity and Clinical Trials to Inform Next-Generation Human Cytomegalovirus Vaccine Development.

Hu X, Wang H, Otero C, Jenks J, Permar S Annu Rev Virol. 2022; 9(1):491-520.

PMID: 35704747 PMC: 10154983. DOI: 10.1146/annurev-virology-100220-010653.

Modified vaccinia Ankara expressing EEHV1A glycoprotein B elicits humoral and cell-mediated immune responses in mice.

Pursell T, Clinton J, Tan J, Peng R, Ling P PLoS One. 2022; 17(3):e0265424.

PMID: 35312707 PMC: 8936464. DOI: 10.1371/journal.pone.0265424.

Clinical, Virologic and Immunologic Correlates of Breast Milk Acquired Cytomegalovirus (CMV) Infections in Very Low Birth Weight (VLBW) Infants in a Newborn Intensive Care Unit (NICU) Setting.

Hernandez-Alvarado N, Shanley R, Schleiss M, Ericksen J, Wassenaar J, Webo L Viruses. 2021; 13(10).

PMID: 34696327 PMC: 8539954. DOI: 10.3390/v13101897.

References

Hanson H, Leiser C, Bandoli G, Pollock B, Karagas M, Armstrong D . Charting the life course: Emerging opportunities to advance scientific approaches using life course research. J Clin Transl Sci. 2021; 5(1):e9. PMC: 8057465. DOI: 10.1017/cts.2020.492. View

Schleiss M . Recombinant cytomegalovirus glycoprotein B vaccine: Rethinking the immunological basis of protection. Proc Natl Acad Sci U S A. 2018; 115(24):6110-6112. PMC: 6004476. DOI: 10.1073/pnas.1806420115. View

Boppana S, Rivera L, Fowler K, Mach M, Britt W . Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med. 2001; 344(18):1366-71. DOI: 10.1056/NEJM200105033441804. View

Baraniak I, Kropff B, Ambrose L, McIntosh M, McLean G, Pichon S . Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies. Proc Natl Acad Sci U S A. 2018; 115(24):6273-6278. PMC: 6004462. DOI: 10.1073/pnas.1800224115. View

Gerna G, Kabanova A, Lilleri D . . Vaccines (Basel). 2019; 7(3). PMC: 6789482. DOI: 10.3390/vaccines7030070. View

Contreras H, Wussow F, Fernandez-Alarcon C, Bierle C, Nguyen J, Diamond D . MVA-Vectored Pentameric Complex (PC) and gB Vaccines Improve Pregnancy Outcome after Guinea Pig CMV Challenge, but Only gB Vaccine Reduces Vertical Transmission. Vaccines (Basel). 2019; 7(4). PMC: 6963609. DOI: 10.3390/vaccines7040182. View

Ynga-Durand M, Dekhtiarenko I, Cicin-Sain L . Vaccine Vectors Harnessing the Power of Cytomegaloviruses. Vaccines (Basel). 2019; 7(4). PMC: 6963789. DOI: 10.3390/vaccines7040152. View

Permar S, Schleiss M, Plotkin S . Advancing Our Understanding of Protective Maternal Immunity as a Guide for Development of Vaccines To Reduce Congenital Cytomegalovirus Infections. J Virol. 2018; 92(7). PMC: 5972872. DOI: 10.1128/JVI.00030-18. View

Tabata T, Petitt M, Fang-Hoover J, Freed D, Li F, An Z . Neutralizing Monoclonal Antibodies Reduce Human Cytomegalovirus Infection and Spread in Developing Placentas. Vaccines (Basel). 2019; 7(4). PMC: 6963214. DOI: 10.3390/vaccines7040135. View

10.

Plotkin S, Wang D, Oualim A, Diamond D, Kotton C, Mossman S . The Status of Vaccine Development Against the Human Cytomegalovirus. J Infect Dis. 2020; 221(Suppl 1):S113-S122. PMC: 7057802. DOI: 10.1093/infdis/jiz447. View

11.

Gomes A, Griffiths P, Reeves M . The Humoral Immune Response Against the gB Vaccine: Lessons Learnt from Protection in Solid Organ Transplantation. Vaccines (Basel). 2019; 7(3). PMC: 6789498. DOI: 10.3390/vaccines7030067. View

12.

Wilski N, Snyder C . From Vaccine Vector to Oncomodulation: Understanding the Complex Interplay between CMV and Cancer. Vaccines (Basel). 2019; 7(3). PMC: 6789822. DOI: 10.3390/vaccines7030062. View

13.

Britt W . Congenital Human Cytomegalovirus Infection and the Enigma of Maternal Immunity. J Virol. 2017; 91(15). PMC: 5512250. DOI: 10.1128/JVI.02392-16. View

14.

Coppola T, Mangold J, Cantrell S, Permar S . Impact of Maternal Immunity on Congenital Cytomegalovirus Birth Prevalence and Infant Outcomes: A Systematic Review. Vaccines (Basel). 2019; 7(4). PMC: 6963523. DOI: 10.3390/vaccines7040129. View

15.

Faure-Bardon V, Magny J, Parodi M, Couderc S, Garcia P, Maillotte A . Sequelae of Congenital Cytomegalovirus Following Maternal Primary Infections Are Limited to Those Acquired in the First Trimester of Pregnancy. Clin Infect Dis. 2019; 69(9):1526-1532. DOI: 10.1093/cid/ciy1128. View

16.

Schleiss M . Congenital cytomegalovirus: Impact on child health. Contemp Pediatr. 2019; 35(7):16-24. PMC: 6368255. View

17.

Manicklal S, Emery V, Lazzarotto T, Boppana S, Gupta R . The "silent" global burden of congenital cytomegalovirus. Clin Microbiol Rev. 2013; 26(1):86-102. PMC: 3553672. DOI: 10.1128/CMR.00062-12. View

18.

Tastad K, Schleiss M, Lammert S, Basta N . Awareness of congenital cytomegalovirus and acceptance of maternal and newborn screening. PLoS One. 2019; 14(8):e0221725. PMC: 6709948. DOI: 10.1371/journal.pone.0221725. View

19.

Gogesch P, Penner I, Krauter S, Buscher N, Grode L, Aydin I . Production Strategies for Pentamer-Positive Subviral Dense Bodies as a Safe Human Cytomegalovirus Vaccine. Vaccines (Basel). 2019; 7(3). PMC: 6789746. DOI: 10.3390/vaccines7030104. View

20.

Nelson C, Huffman T, Jenks J, Cisneros de la Rosa E, Xie G, Vandergrift N . HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions. Proc Natl Acad Sci U S A. 2018; 115(24):6267-6272. PMC: 6004431. DOI: 10.1073/pnas.1800177115. View